SCHEMBL3324337

SCHEMBL3324337

O=Cc1sc(-c2ccc(F)cc2)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 5/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CHUK O15111 1/20 0.41
MEN1 O00255 1/20 0.37
JAK2 O60674 1/20 0.37
EIF2AK2 P19525 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PDPK1 O15530 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
PTPN1 P18031 1/20 0.36
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594365 0.76 IKBKB (0.42) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3325856 0.76 IKBKB (0.38) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17559517 0.74 KDM4E (0.33) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3597485 0.74 SNCA (0.53) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL27797494 0.73 IKBKB (0.40) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL31196237 0.71
SCHEMBL3601307 0.71 PTPN1 (0.58) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3613642 0.70 IKBKB (0.38) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3326395 0.68 PDPK1 (0.35) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17559529 0.68 KDM4E (0.33) IKBKBCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137388-A1 Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof DENOVAMED INC. (CA) 2010-06-03 US disclosed
WO-2008128321-A1 THERAPEUTIC PRO-ANTIBIOTIC AGENTS AND METHODS OF USE THEREOF DENOVAMED INC. (CA) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137388-A1 Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof NAT1, NAPEPLD, NR1I2 IKBKB 3041/4885CYP1A2 48/4885CYP3A4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.